Numab Therapeutics AG

Multi-specific antibodies that enable the pursuit of novel therapeutic strategies.

Add To Watchlist
General Information
Company Name
Numab Therapeutics AG
Founded Year
2011
Location (Offices)
Horgen, Switzerland +1
Founders / Decision Makers
David Urech - CSO, and Co-CEO, Founder Oliver Middendorp - CBO, Co-CEO, and Co-Founder Peter Lichtlen - CMO and Co-Founder Tea Gunde - Head of Pharmacology Sebastian Meyer - Chief Operating Officer Roland Helfenstein - Chief Financial Officer
Number of Employees
68
Industries
Biopharma, Biotechnology, Health Care +2
Funding Stage
Series C
Social Media

Numab Therapeutics AG - Company Profile

Numab Therapeutics AG is a Swiss-based biopharmaceutical company founded in 2011. The company specializes in developing multi-specific antibody-based immunotherapies for inflammation and cancer. With a proprietary platform called λ-Cap™ and MATCH™, Numab has a unique advantage in overcoming historical drug discovery barriers. Their lead candidate, NM26, targets IL-4/13 and IL-31 for best-in-class efficacy in treating atopic dermatitis and other potential indications. The company recently received a Series C investment on December 5, 2022, with HBM Healthcare Investments participating as the investor. Numab's focus on innovative therapeutic strategies and its strong investor backing positions it as a key player in the biopharma and biotechnology sectors, with potential to deliver significant patient benefits.

Taxonomy: multi-specific antibodies, therapeutic strategies, immunotherapies, inflammation, cancer, drug discovery, pipeline, precision medicine, atopic dermatitis, therapeutic design, patient benefits, innovation, biopharmaceuticals

Funding Rounds & Investors of Numab Therapeutics AG (3)

View All
Funding Stage Amount No. Investors Investors Date
Series C Unknown 1
HBM Healthcare Investments, investor in Numab Therapeutics AG's Series C round
05 Dec 2022
Series C Fr.100.00M 9
Novo Holdings, investor in Numab Therapeutics AG's Series C round HBM Healthcare Investments, investor in Numab Therapeutics AG's Series C round BlackRock, investor in Numab Therapeutics AG's Series C round Forbion, investor in Numab Therapeutics AG's Series C round HBM Partners, investor in Numab Therapeutics AG's Series C round Octagon Capital Advisors, investor in Numab Therapeutics AG's Series C round RTW Investments, investor in Numab Therapeutics AG's Series C round Cormorant Asset Management, investor in Numab Therapeutics AG's Series C round
Biotechnology Value Fund 		19 May 2021
Series B Fr.22.00M - 12 Dec 2019

Latest News of Numab Therapeutics AG

View All

No recent news or press coverage available for Numab Therapeutics AG.

Similar Companies to Numab Therapeutics AG

View All
ExeVir - Similar company to Numab Therapeutics AG
ExeVir Rapid Viral control in a world that needs it
EpiBiologics - Similar company to Numab Therapeutics AG
EpiBiologics Next Generation Protein Degradation
Enlaza Therapeutics - Similar company to Numab Therapeutics AG
Enlaza Therapeutics Pioneering Covalent Biologics
Mabqi - Similar company to Numab Therapeutics AG
Mabqi Your key partner for breakthrough antibody discovery
Spyre Therapeutics - Similar company to Numab Therapeutics AG
Spyre Therapeutics Engineering for new heights in the treatment of inflammatory bowel disease
Circle Decoration Circle Decoration

Want to dive deeper into Numab Therapeutics AG? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now